Back to news

Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology

Business Wire•16/11/2026•08:00 ET
0

Key Highlights

  • ➤Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront
  • ➤OLN324 is a Phase 3 bispecific antibody targeting VEGF and Ang2
  • ➤Deal includes up to approximately $1.125 billion in regulatory and commercial milestones
  • ➤Blackstone will provide $750 million to fully fund OLN324’s Phase 3 development
  • ➤Transaction is expected to close before the end of 2026, subject to approvals

Expert Statements

Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control”

Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology

* Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in